PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid) (PROBLEMA)
Randomized Trial of Epsilon Aminocaproic Acid Versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients With Hematological Malignancies
Sponsor: Emory University
Terminated
Slow accrual
Other terminated trials from Emory University
Other Hematological Malignancies trials with similar outcome
Listed as NCT02074436, this PHASE2 trial focuses on Hematological Malignancies and Thrombocytopenia and remains terminated or withdrawn. Sponsored by Emory University, it has been updated 11 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2021 — Jun 2022 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jun 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Emory University
For direct contact, visit the study record on ClinicalTrials.gov .